


<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app12.us.archive.org';v.server_ms=469;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include -->  

        <title>Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. Report of the Guideline Development Subcommittee of the American Academy of Neurology. | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/web/20180713033519im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/web/20180713033519im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/web/20180713033519im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/web/20180713033519im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/web/20180713033519/https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/web/20180713033519im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/web/20180713033519cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180713033519js_/https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&amp;subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//web.archive.org/web/20180713033519if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180713033519/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//web.archive.org/web/20180713033519if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180713033519/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="https://web.archive.org/web/20180713033519/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="https://web.archive.org/web/20180713033519/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/web/20180713033519/https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source media="(min-width: 960px)" srcset="/web/20180713033519im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
				        <source srcset="/web/20180713033519im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
				        <img src="/web/20180713033519im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/web/20180713033519/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/web/20180713033519/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/web/20180713033519/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/web/20180713033519/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/web/20180713033519/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In"/>
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/web/20180713033519/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/web/20180713033519/https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="/web/20180713033519/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/web/20180713033519/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/web/20180713033519/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/web/20180713033519/https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="/web/20180713033519/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/web/20180713033519/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/web/20180713033519/https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="/web/20180713033519/https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/web/20180713033519/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/web/20180713033519/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/web/20180713033519/https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/web/20180713033519/https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/web/20180713033519/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180713033519/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

    <!-- CONTENT HEADER -->
    <div class="content-header">
        <ul class="content-header-meta">
            <li class="prefix-icon guideline">Guideline Summary</li>
            <li>NGC:010200</li>
            <li>2014 Jan 14
            </li>            
                                </ul>
        <div>
                <h1>Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. Report of the Guideline Development Subcommittee of the American Academy of Neurology.</h1>
        </div>
    </div>
    <!-- /.content-header-meta -->

        <!-- CONTENT TABS -->
        <ul class="content-tabs">
            <li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
            <li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
            <li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
            <li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
        </ul>
        <div id="developer-tab" class="is-active content-tab-panel">
                <ul class="developer-list">
        <li><a href="/web/20180713033519/https://www.guideline.gov/search?f_Guideline_Developer_String=American%20Academy%20of%20Neurology&amp;fLockTerm=American%2BAcademy%2Bof%2BNeurology">American Academy of Neurology</a></li>
                        <li>   
                                <a id="39" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
                </ul>
        </div>
    <!-- /.content-tab-panel -->
    <div id="source-tab" class="content-tab-panel">
<table><tr><td>Minden SL, Feinstein A, Kalb RC, Miller D, Mohr DC, Patten SB, Bever C Jr, Schiffer RB, Gronseth GS, Narayanaswami P. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014 Jan 14;82(2):174-81. [40 references] <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24376275" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table>                    <p><a href="/web/20180713033519/https://www.guideline.gov/Home/Disclaimer?id=47759&amp;contentType=fulltextlink&amp;redirect=https%253a%252f%252fwww.aan.com%252fGuidelines%252f">View the original guideline documentation</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="status-tab" class="content-tab-panel">
            <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="classification-tab" class="content-tab-panel">


        
                            <h4>UMLS Concepts <a href="/web/20180713033519/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
                <div class="field">
                    <h5 class="field-label">ICD9CM</h5>
                    <div class="field-content">
<a href="/web/20180713033519/https://www.guideline.gov/search?f_ICD9CM_CUI=C0005586&amp;fLockTerm=Bipolar+disorder%2c+unspecified">Bipolar disorder, unspecified</a>
 (296.80), <a href="/web/20180713033519/https://www.guideline.gov/search?f_ICD9CM_CUI=C0085633&amp;fLockTerm=Emotional+lability">Emotional lability</a>
 (799.24), <a href="/web/20180713033519/https://www.guideline.gov/search?f_ICD9CM_CUI=C0026769&amp;fLockTerm=Multiple+sclerosis">Multiple sclerosis</a>
 (340), <a href="/web/20180713033519/https://www.guideline.gov/search?f_ICD9CM_CUI=C2316460&amp;fLockTerm=Pseudobulbar+affect">Pseudobulbar affect</a>
 (310.81), <a href="/web/20180713033519/https://www.guideline.gov/search?f_ICD9CM_CUI=C1456428&amp;fLockTerm=Unspecified+persistent+mental+disorders+due+to+conditions+classified+elsewhere">Unspecified persistent mental disorders due to conditions classified elsewhere</a>
 (294.9), <a href="/web/20180713033519/https://www.guideline.gov/search?f_ICD9CM_CUI=C0033975&amp;fLockTerm=Unspecified+psychosis">Unspecified psychosis</a>
 (298.9)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MSH</h5>
                    <div class="field-content">
<a href="/web/20180713033519/https://www.guideline.gov/search?f_MSH_CUI=C0003469&amp;fLockTerm=Anxiety+Disorders">Anxiety Disorders</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MSH_CUI=C0005586&amp;fLockTerm=Bipolar+Disorder">Bipolar Disorder</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MSH_CUI=C0009244&amp;fLockTerm=Cognitive+Therapy">Cognitive Therapy</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MSH_CUI=C1269683&amp;fLockTerm=Depressive+Disorder%2c+Major">Depressive Disorder, Major</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MSH_CUI=C0011816&amp;fLockTerm=Dextromethorphan">Dextromethorphan</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MSH_CUI=C0004936&amp;fLockTerm=Mental+Disorders">Mental Disorders</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MSH_CUI=C0026769&amp;fLockTerm=Multiple+Sclerosis">Multiple Sclerosis</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MSH_CUI=C0027902&amp;fLockTerm=Neuropsychological+Tests">Neuropsychological Tests</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MSH_CUI=C0033975&amp;fLockTerm=Psychotic+Disorders">Psychotic Disorders</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MSH_CUI=C0034414&amp;fLockTerm=Quinidine">Quinidine</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MSH_CUI=C0162648&amp;fLockTerm=Telemedicine">Telemedicine</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MTH</h5>
                    <div class="field-content">
<a href="/web/20180713033519/https://www.guideline.gov/search?f_MTH_CUI=C0003469&amp;fLockTerm=Anxiety+Disorders">Anxiety Disorders</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MTH_CUI=C0451022&amp;fLockTerm=Beck+depression+inventory">Beck depression inventory</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MTH_CUI=C0005586&amp;fLockTerm=Bipolar+Disorder">Bipolar Disorder</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MTH_CUI=C0009244&amp;fLockTerm=Cognitive+Therapy">Cognitive Therapy</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MTH_CUI=C0011816&amp;fLockTerm=Dextromethorphan">Dextromethorphan</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MTH_CUI=C0233459&amp;fLockTerm=Emotional+disorder">Emotional disorder</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MTH_CUI=C1269683&amp;fLockTerm=MAJOR+DEPRESSIVE+DISORDER">MAJOR DEPRESSIVE DISORDER</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MTH_CUI=C0004936&amp;fLockTerm=Mental+disorders">Mental disorders</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MTH_CUI=C0085633&amp;fLockTerm=Mood+swings">Mood swings</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MTH_CUI=C0026769&amp;fLockTerm=Multiple+Sclerosis">Multiple Sclerosis</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MTH_CUI=C0033975&amp;fLockTerm=Psychotic+Disorders">Psychotic Disorders</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MTH_CUI=C0034414&amp;fLockTerm=Quinidine">Quinidine</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_MTH_CUI=C0162648&amp;fLockTerm=Telemedicine">Telemedicine</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">PDQ</h5>
                    <div class="field-content">
<a href="/web/20180713033519/https://www.guideline.gov/search?f_PDQ_CUI=C0003469&amp;fLockTerm=anxiety+disorder">anxiety disorder</a>
, <a href="/web/20180713033519/https://www.guideline.gov/search?f_PDQ_CUI=C0034414&amp;fLockTerm=quinidine">quinidine</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SNOMEDCT_US</h5>
                    <div class="field-content">
<a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0003469&amp;fLockTerm=Anxiety+disorder">Anxiety disorder</a>
 (197480006), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C2960240&amp;fLockTerm=Assessment+using+Beck+depression+inventory">Assessment using Beck depression inventory</a>
 (446765009), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0451022&amp;fLockTerm=Beck+depression+inventory">Beck depression inventory</a>
 (273306008), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0005586&amp;fLockTerm=Bipolar+disorder">Bipolar disorder</a>
 (13746004), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0009244&amp;fLockTerm=Cognitive+therapy">Cognitive therapy</a>
 (183383008), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0009244&amp;fLockTerm=Cognitive+therapy">Cognitive therapy</a>
 (228553007), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0009244&amp;fLockTerm=Cognitive+therapy">Cognitive therapy</a>
 (228557008), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0009244&amp;fLockTerm=Cognitive+therapy">Cognitive therapy</a>
 (304891004), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0011816&amp;fLockTerm=Dextromethorphan">Dextromethorphan</a>
 (2016004), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0011816&amp;fLockTerm=Dextromethorphan">Dextromethorphan</a>
 (387114001), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0451182&amp;fLockTerm=General+health+questionnaire">General health questionnaire</a>
 (273479001), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C1269683&amp;fLockTerm=Major+depressive+disorder">Major depressive disorder</a>
 (370143000), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0004936&amp;fLockTerm=Mental+disorder">Mental disorder</a>
 (74732009), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0085633&amp;fLockTerm=Mood+swings">Mood swings</a>
 (18963009), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0026769&amp;fLockTerm=Multiple+sclerosis">Multiple sclerosis</a>
 (192928003), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0026769&amp;fLockTerm=Multiple+sclerosis">Multiple sclerosis</a>
 (24700007), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0027902&amp;fLockTerm=Neuropsychological+testing">Neuropsychological testing</a>
 (307808008), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C2316460&amp;fLockTerm=Pseudobulbar+affect">Pseudobulbar affect</a>
 (432776007), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0033975&amp;fLockTerm=Psychotic+disorder">Psychotic disorder</a>
 (69322001), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0034414&amp;fLockTerm=Quinidine">Quinidine</a>
 (31306009), <a href="/web/20180713033519/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0034414&amp;fLockTerm=Quinidine">Quinidine</a>
 (372697008)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
    </div>
        <!-- /.content-tab-panel -->
        <!-- /.content-tab-panel -->
        <!-- TOOLBAR -->
        <div class="content-toolbar">

            <!-- Primary -->
            <ul class="tools primary-tools">
                <li class="dropdown tool sections">
                    <a href="#" class="tool-button">Sections</a>
                    <div class="dropdown-panel">
                            <ul class="section-links">
                                    <li><a href="#420" class="section-mark">Recommendations</a></li>
                                    <li><a href="#396" class="section-mark">Scope</a></li>
                                    <li><a href="#405" class="section-mark">Methodology</a></li>
                                    <li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
                                    <li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
                                    <li><a href="#432" class="section-mark">Qualifying Statements</a></li>
                                    <li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
                                    <li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
                                    <li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
                                    <li><a href="#99999" class="section-mark">Disclaimer</a></li>
                            </ul>    
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
            </ul>

            <!-- Other -->
            <ul class="tools other-tools">
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Download</a>

                    <div class="dropdown-panel">
                        <ul>
                            <li><a href="/web/20180713033519/https://www.guideline.gov/summaries/downloadcontent/ngc-10200?contentType=pdf" class="pdf">.PDF 122.8 kb</a></li>
                            <li><a href="/web/20180713033519/https://www.guideline.gov/summaries/downloadcontent/ngc-10200?contentType=word" class="word">Word Document 318.1 kb</a></li>
                            <li><a href="/web/20180713033519/https://www.guideline.gov/summaries/downloadcontent/ngc-10200?contentType=xml" class="xml">.XML 61.0 kb</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Share</a>
                    <div class="dropdown-panel">
                        <ul class="toolbar-social">
                            <li><a target="_blank" href="https://web.archive.org/web/20180713033519/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/47759/evidencebased-guideline-assessment-and-management-of-psychiatric-disorders-in-individuals-with-ms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology" class="facebook">Facebook</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180713033519/https://twitter.com/share?text=&amp;url=https://www.guideline.gov/summaries/summary/47759/evidencebased-guideline-assessment-and-management-of-psychiatric-disorders-in-individuals-with-ms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology" class="twitter">Twitter</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180713033519/https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.guideline.gov/summaries/summary/47759/evidencebased-guideline-assessment-and-management-of-psychiatric-disorders-in-individuals-with-ms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology&amp;title=&amp;summary=&amp;source=" class="linkedin">Linkedin</a></li>
                            <li><a href="https://web.archive.org/web/20180713033519/mailto:/?Subject=AHRQ: Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. Report of the Guideline Development Subcommittee of the American Academy of Neurology.&amp;body=https://www.guideline.gov/summaries/summary/47759/evidencebased-guideline-assessment-and-management-of-psychiatric-disorders-in-individuals-with-ms-report-of-the-guideline-development-subcommittee-of-the-american-academy-of-neurology" class="email">Email</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Cite</a>
                    <div class="dropdown-panel citation">
                        <p class="text-label"><label for="citation">Citation: </label></p>
                        <textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. Report of the Guideline Development Subcommittee of the American Academy of Neurology. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2014 Jan 14. [cited 2018 Jul 13]. Available: https://www.guideline.gov</textarea>                        
                        <p class="text-label">Download citation file: </p>
                        <ul>
                            <li><a href="/web/20180713033519/https://www.guideline.gov/summaries/citedownload/47759?format=ris">RIS (Zotero)</a></li>
                            <li><a href="/web/20180713033519/https://www.guideline.gov/summaries/citedownload/47759?format=enw">EndNote</a></li>
                            <li><a href="/web/20180713033519/https://www.guideline.gov/summaries/citedownload/47759?format=bibtex">BibTex</a></li>
                            <li><a href="/web/20180713033519/https://www.guideline.gov/summaries/citedownload/47759?format=txt">Medlars</a></li>
                            <li><a href="/web/20180713033519/https://www.guideline.gov/summaries/citedownload/47759?format=ris">ProCite</a></li>
                            <li><a href="/web/20180713033519/https://www.guideline.gov/summaries/citedownload/47759">RefWorks</a></li>
                            <li><a href="/web/20180713033519/https://www.guideline.gov/summaries/citedownload/47759?format=ris">Reference Manager</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                                
                <li class="tool">
                        <a href="#" id="47759" data-alert="SignInLanding" class="tool-button save-link">Save</a>
                </li>
            </ul>

            <!-- Accordion -->
            <ul class="tools accordion-controls">
                <li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
                <li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
            </ul>
        </div>
        <!-- /.toolbar -->


		<!-- ARTICLE -->
		<div class="article" id="article">
			




    <!-- ACCORDION -->
    <div class="accordion-container" role="tablist" multiselectable="true">
                <h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Major Recommendations</a></h3>
                    <p><div class="content_para"><p>Definitions of the levels of the recommendations (<strong>A, B, C, U</strong>) and classification of the evidence (<strong>Class I-IV</strong>) are provided at the end of the "Major Recommendations" field.</p>
<p><span style="text-decoration: underline;"><strong>Screening and Diagnosis</strong></span></p>
<p><strong>What Clinical Evaluation Procedures and Screening and Diagnostic Tools Can Be Used to Accurately Identify Symptoms and Make Diagnoses of Emotional Disorders in Individuals with Multiple Sclerosis (MS)?</strong></p>
<p><em>Conclusions and Recommendations</em></p>
<p>In individuals with MS, the Center for Neurologic Study Emotional Lability Scale (CNS-LS) is possibly effective and may be considered for screening for pseudobulbar affect (PBA) (<strong>Level C, 1 Class II study</strong> [Smith et al., 2004]). The General Health Questionnaire (GHQ) (Goldberg &amp; Hillier, 1979) is possibly effective and may be considered for identifying individuals with broadly defined emotional disturbances (<strong>Level C, 1 Class II study</strong> [Rabins &amp; Brooks, 1981]). The Beck Depression Inventory (BDI) (Beck et al., 1961) and a 2-question screen (Whooley et al., 1997) are possibly effective and may be considered for identifying individuals with major depressive disorder (MDD) (<strong>Level C, 1 Class II study each</strong> [Sullivan et al., 1995; Mohr et al., 2007]). There is insufficient evidence to support/refute using the Center for Epidemiologic Studies Depression Rating Scale (CES-D) (Radloff, 1977) to screen for depressive symptoms (Pandya, Metz, &amp; Patten, 2005) or a single question to screen for MDD (Vahter et al., 2007) (<strong>Level U, 1 Class III study each</strong>); the possibility that somatic or neurovegetative symptoms negatively affect the accuracy of BDI results (<strong>Level U, 2 conflicting Class III studies</strong>) (Mohr et al., 1997; Randolph et al., 2000); and the use of specific instruments or clinical evaluation procedures to diagnose emotional disorders in individuals with MS (<strong>Level U</strong>).</p>
<p><em>Clinical Context</em></p>
<p>Because emotional disorders may be unrecognized in medical settings, validated screening tools might improve identification of individuals who could benefit from further evaluation and treatment. The true positive rate of a screening tool depends not only on its sensitivity but also on the point prevalence of the disorder in the population under study. Clinically, false-positive results are not a major concern because individuals with the conditions typically identified (e.g., adjustment and subthreshold depressive disorders) can benefit from further assessment. Administratively, however, screening tools with high false-positive rates unnecessarily increase resource use.</p>
<p><span style="text-decoration: underline;"><strong>Treatments</strong></span></p>
<p><strong>What Are the Effective Treatments for Disorders of Mood in Individuals with MS?</strong></p>
<p><em>Conclusion and Recommendations</em></p>
<p>For individuals with MS, a 16-week program of individual telephone-administered cognitive behavioral therapy (T-CBT) program is possibly effective and may be considered in treating depressive symptoms (<strong>Level C, 1 Class II study</strong> [Mohr et al., 2005], <strong>1 Class III study</strong> [Mohr, et al., 2000]). There is insufficient evidence to support/refute the efficacy and use of 1) sertraline (Mohr et al., 2001), desipramine (Schiffer &amp; Wineman, 1990), paroxetine (Ehde et al., 2008), individual in-person cognitive behavioral therapy (CBT) (Mohr et al., 2001), individual in-person CBT plus relaxation training (Foley et al., 1987), or CBT-based group therapy (Forman &amp; Lincoln, 2010) for depressive symptoms; or 2) individual in-person CBT plus relaxation training (Foley et al., 1987), group relaxation and imagery (Maguire, 1996), or CBT-based group therapy (Forman &amp; Lincoln, 2010) for anxiety (<strong>Level U, 1 Class III study</strong> each).</p>
<p><em>Clinical Context</em></p>
<p>There is evidence supporting the efficacy of pharmacologic and nonpharmacologic therapies for depressed mood and anxiety in individuals without MS. Despite the lack of evidence in individuals with MS, these therapies are frequently used to treat emotional disorders in this population.</p>
<p><strong>What Are the Effective Treatments for Disorders of Affect in Individuals with MS?</strong></p>
<p><em>Conclusion and Recommendations</em></p>
<p>Dextromethorphan and quinidine (DM/Q) is possibly effective and safe and may be considered for treating individuals with MS with PBA (<strong>Level C, 1 Class II study</strong>) (Panitch et al., 2006).</p>
<p><em>Clinical Context</em></p>
<p>DM/Q is the only drug approved by the US Food and Drug Administration for PBA treatment, although other drugs are used in clinical practice (e.g., selective serotonin reuptake inhibitors, tricyclic antidepressants). There are no randomized placebo-controlled trials of these other agents.</p>
<p><span style="text-decoration: underline;"><strong>Definitions</strong></span>:</p>
<p><strong><span style="text-decoration: underline;">Classification of Evidence</span></strong></p>
<p><strong>Screening Articles</strong></p>
<p><strong>Class I</strong>: A statistical, population based sample of patients studied at a uniform point in time (usually early) during the course of the condition. All patients undergo the intervention of interest. The outcome, if not objective, is determined in an evaluation that is masked to the patients' clinical presentations.</p>
<p><strong>Class II</strong>: A statistical, non-referral clinic based sample of patients studied at a uniform point in time (usually early) during the course of the condition. Most patients undergo the intervention of interest. The outcome, if not objective, is determined in an evaluation that is masked to the patients' clinical presentations.</p>
<p><strong>Class III</strong>: A sample of patients studied during the course of the condition. Some patients undergo the intervention of interest. The outcome, if not objective, is determined in an evaluation by someone other than the treating physician.</p>
<p><strong>Class IV</strong>: Studies not meeting Class I, II, or III criteria, including consensus, expert opinion or a case report.</p>
<p><strong>Diagnostic Articles</strong></p>
<p><strong>Class I</strong>: A cohort study with prospective data collection of a broad spectrum of persons with the suspected condition, using an acceptable reference standard for case definition. The diagnostic test is objective or performed and interpreted without knowledge of the patient's clinical status. Study results allow calculation of measures of diagnostic accuracy.</p>
<p><strong>Class II</strong>: A case control study of a broad spectrum of persons with the condition established by an acceptable reference standard compared to a broad spectrum of controls or a cohort study where a broad spectrum of persons with the suspected condition where the data was collected retrospectively. The diagnostic test is objective or performed and interpreted without knowledge of disease status. Study results allow calculation of measures of diagnostic accuracy.</p>
<p><strong>Class III</strong>: A case control study or cohort study where either persons with the condition or controls are of a narrow spectrum. The condition is established by an acceptable reference standard. The reference standard and diagnostic test are objective or performed and interpreted by different observers. Study results allow calculation of measures of diagnostic accuracy.</p>
<p><strong>Class IV</strong>: Studies not meeting Class I, II, or III criteria including consensus, expert opinion, or a case report.</p>
<p><strong>Therapeutic Articles</strong></p>
<p><strong>Class I</strong>: A randomized, controlled clinical trial of the intervention of interest with masked or objective outcome assessment, in a representative population. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.</p>
<p>The following are also required:</p>
<ol style="list-style-type: lower-alpha;">
    <li>Concealed allocation </li>
    <li>Primary outcome(s) clearly defined </li>
    <li>Exclusion/inclusion criteria clearly defined </li>
    <li>Adequate accounting for dropouts (with at least 80% of enrolled subjects completing the study) and crossovers with numbers sufficiently low to have minimal potential for bias. </li>
    <li>For noninferiority or equivalence trials claiming to prove efficacy for one or both drugs, the following are also required*:
    <ol style="list-style-type: decimal;" start="1">
        <li>The authors explicitly state the clinically meaningful difference to be excluded by defining the threshold for equivalence or noninferiority. </li>
        <li>The standard treatment used in the study is substantially similar to that used in previous studies establishing efficacy of the standard treatment (e.g., for a drug, the mode of administration, dose and dosage adjustments are similar to those previously shown to be effective). </li>
        <li>The inclusion and exclusion criteria for patient selection and the outcomes of patients on the standard treatment are comparable to those of previous studies establishing efficacy of the standard treatment. </li>
        <li>The interpretation of the results of the study is based upon a per protocol analysis that takes into account dropouts or crossovers. </li>
    </ol>
    </li>
</ol>
<p><strong>Class II</strong>: A randomized controlled clinical trial of the intervention of interest in a representative population with masked or objective outcome assessment that lacks one criteria a&ndash;e above or a prospective matched cohort study with masked or objective outcome assessment in a representative population that meets b&ndash;e above. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.</p>
<p><strong>Class III</strong>: All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome is independently assessed, or independently derived by objective outcome measurement.**</p>
<p><strong>Class IV</strong>: Studies not meeting Class I, II, or III criteria including consensus or expert opinion.</p>
<p class="Note">*Note that numbers 1-3 in Class Ie are required for Class II in equivalence trials. If any one of the three is missing, the class is automatically downgraded to Class III.</p>
<p class="Note">**Objective outcome measurement: an outcome measure that is unlikely to be affected by an observer's (patient, treating physician, investigator) expectation or bias (e.g., blood tests, administrative outcome data).</p>
<p><strong>Classification of Recommendations</strong></p>
<p><strong>Level A</strong> = Established as effective, ineffective or harmful (or established as useful/predictive or not useful/predictive) for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies.)*</p>
<p><strong>Level B</strong> = Probably effective, ineffective or harmful (or probably useful/predictive or not useful/predictive) for the given condition in the specified population. (Level B rating requires at least one Class I study or two consistent Class II studies.)</p>
<p><strong>Level C</strong> = Possibly effective, ineffective or harmful (or possibly useful/predictive or not useful/predictive) for the given condition in the specified population. (Level C rating requires at least one Class II study or two consistent Class III studies.)</p>
<p><strong>Level U</strong> = Data inadequate or conflicting; given current knowledge, treatment (test, predictor) is unproven.</p>
<p class="Note">* In exceptional cases, one convincing Class I study may suffice for an "A" recommendation if 1) all criteria are met, 2) the magnitude of effect is large (relative rate improved outcome &gt;5 and the lower limit of the confidence interval is &gt;2).</p></div></p>
                        <h3><a href="#">Clinical Algorithm(s)</a></h3>
                    <p><div class="content_para"><p>None provided</p></div></p>

            </div>
                <h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Disease/Condition(s)</a></h3>
                    <p><div class="content_para"><p>Multiple sclerosis (MS) and psychiatric disorders, including:</p>
<ul style="list-style-type: disc;">
    <li>Pseudobulbar affect (PBA) </li>
    <li>Major depressive disorder (MDD) </li>
    <li>Bipolar disorder </li>
    <li>Anxiety disorder </li>
    <li>Psychotic disorders </li>
</ul></div></p>
                        <h3><a href="#">Guideline Category</a></h3>
                    <p>Diagnosis</p>
                    <p>Evaluation</p>
                    <p>Management</p>
                    <p>Screening</p>
                    <p>Treatment</p>
                        <h3><a href="#">Clinical Specialty</a></h3>
                    <p>Family Practice</p>
                    <p>Neurology</p>
                    <p>Psychiatry</p>
                    <p>Psychology</p>
                        <h3><a href="#">Intended Users</a></h3>
                    <p>Advanced Practice Nurses</p>
                    <p>Nurses</p>
                    <p>Physician Assistants</p>
                    <p>Physicians</p>
                    <p>Psychologists/Non-physician Behavioral Health Clinicians</p>
                        <h3><a href="#">Guideline Objective(s)</a></h3>
                    <p><div class="content_para"><p>To make evidence-based recommendations for screening, diagnosing, and treating psychiatric disorders in individuals with multiple sclerosis (MS)</p></div></p>
                        <h3><a href="#">Target Population</a></h3>
                    <p><div class="content_para"><p>Individuals with multiple sclerosis (MS) and possible emotional disorders</p></div></p>
                        <h3><a href="#">Interventions and Practices Considered</a></h3>
                    <p><div class="content_para"><p><strong>Screening/Diagnosis</strong></p>
<p>Screening tools, including:</p>
<ul style="list-style-type: disc;">
    <li>Center for Neurologic Study Emotional Lability Scale (CNS-LS) </li>
    <li>General Health Questionnaire (GHQ) </li>
    <li>Beck Depression Inventory (BDI) </li>
    <li>2-question screen </li>
</ul>
<p><strong>Treatment</strong></p>
<ol style="list-style-type: decimal;" start="1">
    <li>Telephone-administered cognitive behavioral therapy program (T-CBT) </li>
    <li>Pharmacologic therapy (dextromethorphan and quinidine [DM/Q]) </li>
</ol>
<p class="Note"><strong>Note</strong>: The following interventions were considered but there was insufficient evidence to be recommended:</p>
<ul class="contentListFont">
    <li>Center for Epidemiologic Studies Depression Rating Scale (CES-D) </li>
    <li>Nonpharmacologic therapy, including individual and group therapies </li>
    <li>Antidepressants </li>
</ul></div></p>
                        <h3><a href="#">Major Outcomes Considered</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Suicide </li>
    <li>Quality of life </li>
</ul></p>

            </div>
                <h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
                    <p>Searches of Electronic Databases</p>
                        <h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
                    <p><div class="content_para"><p>In February 2007, the authors searched the MEDLINE, EMBASE, CINAHL, Web of Science, and Cochrane databases in all languages, using the MeSH term and its text word synonyms and key words for the topics addressed by the clinical questions (see Appendix e-3 of the data supplement for search strategy and terms [see the "Availability of Companion Documents" field]). A total of 4,540 citations were retrieved. The authors updated the search in August 2011 and identified 605 additional citations, making a combined total of 5,145 citations. At least 2 authors reviewed all 5,145 abstracts. The review yielded 953 articles to be submitted to full-text review.</p></div></p>
                        <h3><a href="#">Number of Source Documents</a></h3>
                    <p><div class="content_para"><p>115 documents were systematically reviewed and rated.</p></div></p>
                        <h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
                    <p>Weighting According to a Rating Scheme (Scheme Given)</p>
                        <h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Classification of Evidence</span></strong></p>
<p><strong>Screening Articles</strong></p>
<p><strong>Class I</strong>: A statistical, population based sample of patients studied at a uniform point in time (usually early) during the course of the condition. All patients undergo the intervention of interest. The outcome, if not objective, is determined in an evaluation that is masked to the patients' clinical presentations.</p>
<p><strong>Class II</strong>: A statistical, non-referral clinic based sample of patients studied at a uniform point in time (usually early) during the course of the condition. Most patients undergo the intervention of interest. The outcome, if not objective, is determined in an evaluation that is masked to the patients' clinical presentations.</p>
<p><strong>Class III</strong>: A sample of patients studied during the course of the condition. Some patients undergo the intervention of interest. The outcome, if not objective, is determined in an evaluation by someone other than the treating physician.</p>
<p><strong>Class IV</strong>: Studies not meeting Class I, II, or III criteria, including consensus, expert opinion or a case report.</p>
<p><strong>Diagnostic Articles</strong></p>
<p><strong>Class I</strong>: A cohort study with prospective data collection of a broad spectrum of persons with the suspected condition, using an acceptable reference standard for case definition. The diagnostic test is objective or performed and interpreted without knowledge of the patient's clinical status. Study results allow calculation of measures of diagnostic accuracy.</p>
<p><strong>Class II</strong>: A case control study of a broad spectrum of persons with the condition established by an acceptable reference standard compared to a broad spectrum of controls or a cohort study where a broad spectrum of persons with the suspected condition where the data was collected retrospectively. The diagnostic test is objective or performed and interpreted without knowledge of disease status. Study results allow calculation of measures of diagnostic accuracy.</p>
<p><strong>Class III</strong>: A case control study or cohort study where either persons with the condition or controls are of a narrow spectrum. The condition is established by an acceptable reference standard. The reference standard and diagnostic test are objective or performed and interpreted by different observers. Study results allow calculation of measures of diagnostic accuracy.</p>
<p><strong>Class IV</strong>: Studies not meeting Class I, II, or III criteria including consensus, expert opinion, or a case report.</p>
<p><strong>Therapeutic Articles</strong></p>
<p><strong>Class I</strong>: A randomized, controlled clinical trial of the intervention of interest with masked or objective outcome assessment, in a representative population. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences. The following are also required:</p>
<ol style="list-style-type: lower-alpha;" start="1">
    <li>Concealed allocation </li>
    <li>Primary outcome(s) clearly defined </li>
    <li>Exclusion/inclusion criteria clearly defined </li>
    <li>Adequate accounting for dropouts (with at least 80% of enrolled subjects completing the study) and crossovers with numbers sufficiently low to have minimal potential for bias. </li>
    <li>For noninferiority or equivalence trials claiming to prove efficacy for one or both drugs, the following are also required*:
    <ol style="list-style-type: decimal;" start="1">
        <li>The authors explicitly state the clinically meaningful difference to be excluded by defining the threshold for equivalence or noninferiority. </li>
        <li>The standard treatment used in the study is substantially similar to that used in previous studies establishing efficacy of the standard treatment (e.g., for a drug, the mode of administration, dose and dosage adjustments are similar to those previously shown to be effective). </li>
        <li>The inclusion and exclusion criteria for patient selection and the outcomes of patients on the standard treatment are comparable to those of previous studies establishing efficacy of the standard treatment. </li>
        <li>The interpretation of the results of the study is based upon a per-protocol analysis that takes into account dropouts or crossovers. </li>
    </ol>
    </li>
</ol>
<p><strong>Class II</strong>: A randomized controlled clinical trial of the intervention of interest in a representative population with masked or objective outcome assessment that lacks one criteria a&ndash;e above or a prospective matched cohort study with masked or objective outcome assessment in a representative population that meets b&ndash;e above. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.</p>
<p><strong>Class III</strong>: All other controlled trials (including well-defined natural history controls or patients serving as own controls) in a representative population, where outcome is independently assessed, or independently derived by objective outcome measurement.**</p>
<p><strong>Class IV</strong>: Studies not meeting Class I, II, or III criteria including consensus or expert opinion.</p>
<p class="Note">*Note that numbers 1-3 in Class Ie are required for Class II in equivalence trials. If any one of the three is missing, the class is automatically downgraded to Class III.</p>
<p class="Note">**Objective outcome measurement: an outcome measure that is unlikely to be affected by an observer's (patient, treating physician, investigator) expectation or bias (e.g., blood tests, administrative outcome data).</p></div></p>
                        <h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
                    <p>Systematic Review with Evidence Tables</p>
                        <h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
                    <p><div class="content_para"><p>Of the 953 articles identified in the literature search, 115 were determined to have data relating to one or more of the clinical questions. These were reviewed and classified according to American Academy of Neurology (AAN) criteria for screening, diagnostic, and therapeutic studies (see Appendix e-4 of the data supplement [see the "Availability of Companion Documents" field]), resulting in 41 Class I&ndash;III studies combined for both searches.&nbsp;The recommendations were linked to the strength of evidence (see Appendix e-5 in the data supplement) and intervention effect size. A third reviewer arbitrated discrepant classifications. The authors excluded case reports, review papers, studies with fewer than 20 subjects, and therapeutic studies that did not specify the psychiatric disorder being treated or report scores on both pre- and posttreatment symptom severity measures. Several articles with prevalence data were evaluated but not cited in the manuscript. These are listed in Appendix e-6 in the data supplement.</p></div></p>
                        <h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
                    <p>Expert Consensus</p>
                        <h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
                    <p><div class="content_para"><p>In November 2006, the American Academy of Neurology Guideline Development Subcommittee convened a panel from North America representing a broad range of relevant expertise, including specialists in psychiatry, psychology, neurology, multiple sclerosis (MS), and guideline development methodology.</p>
<p>The project development plan had 9 clinical questions. The authors found evidence to support recommendations for the 3 listed below:</p>
<ol style="list-style-type: decimal;" start="1">
    <li>What clinical evaluation procedures and screening and diagnostic tools can be used to accurately identify symptoms and make diagnoses of emotional disorders in individuals with MS? </li>
    <li>What are the effective treatments for disorders of mood in individuals with MS? </li>
    <li>What are the effective treatments for disorders of affect in individuals with MS? </li>
</ol></div></p>
                        <h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong>Classification of Recommendations</strong></p>
<p><strong>Level A</strong> = Established as effective, ineffective or harmful (or established as useful/predictive or not useful/predictive) for the given condition in the specified population. (Level A rating requires at least two consistent Class I studies.)*</p>
<p><strong>Level B</strong> = Probably effective, ineffective or harmful (or probably useful/predictive or not useful/predictive) for the given condition in the specified population. (Level B rating requires at least one Class I study or two consistent Class II studies.)</p>
<p><strong>Level C </strong>= Possibly effective, ineffective or harmful (or possibly useful/predictive or not useful/predictive) for the given condition in the specified population. (Level C rating requires at least one Class II study or two consistent Class III studies.)</p>
<p><strong>Level U</strong> = Data inadequate or conflicting; given current knowledge, treatment (test, predictor) is unproven.</p>
<p class="Note">* In exceptional cases, one convincing Class I study may suffice for an "A" recommendation if 1) all criteria are met, 2) the magnitude of effect is large (relative rate improved outcome &gt;5 and the lower limit of the confidence interval is &gt;2).</p></div></p>
                        <h3><a href="#">Cost Analysis</a></h3>
                    <p><div class="content_para"><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div></p>
                        <h3><a href="#">Method of Guideline Validation</a></h3>
                    <p>External Peer Review</p>
                    <p>Internal Peer Review</p>
                        <h3><a href="#">Description of Method of Guideline Validation</a></h3>
                    <p><div class="content_para"><p>Drafts of the guideline have been reviewed by at least 3 American Academy of Neurology (AAN) committees, a network of neurologists, <em>Neurology&reg;</em> peer reviewers, and representatives from related fields.</p>
<p>The guideline was approved by the Guideline Development Subcommittee on January 12, 2013; by the Practice Committee on February 17, 2013; and by the AAN Board of Directors on October 2, 2013.</p></div></p>

            </div>
                <h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">References Supporting the Recommendations</a></h3>
                    <p><table><tr><td>Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561-71.</td></tr></table></p>
                    <p><table><tr><td>Ehde DM, Kraft GH, Chwastiak L, Sullivan MD, Gibbons LE, Bombardier CH, Wadhwani R. Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. Gen Hosp Psychiatry. 2008 Jan-Feb;30(1):40-8.</td></tr></table></p>
                    <p><table><tr><td>Foley FW, Bedell JR, LaRocca NG, Scheinberg LC, Reznikoff M. Efficacy of stress-inoculation training in coping with multiple sclerosis. J Consult Clin Psychol. 1987 Dec;55(6):919-22. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3693660" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Forman AC, Lincoln NB. Evaluation of an adjustment group for people with multiple sclerosis: a pilot randomized controlled trial. Clin Rehabil. 2010 Mar;24(3):211-21. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20026575" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. Psychol Med. 1979 Feb;9(1):139-45. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=424481" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Maguire BL. The effects of imagery on attitudes and moods in multiple sclerosis patients. Altern Ther Health Med. 1996 Sep;2(5):75-9. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8795941" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J Consult Clin Psychol. 2001 Dec;69(6):942-9. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11777121" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Mohr DC, Goodkin DE, Likosky W, Beutler L, Gatto N, Langan MK. Identification of Beck Depression Inventory items related to multiple sclerosis. J Behav Med. 1997 Aug;20(4):407-14. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9298438" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Mohr DC, Hart SL, Julian L, Catledge C, Honos-Webb L, Vella L, Tasch ET. Telephone-administered psychotherapy for depression. Arch Gen Psychiatry. 2005 Sep;62(9):1007-14. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16143732" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Mohr DC, Hart SL, Julian L, Tasch ES. Screening for depression among patients with multiple sclerosis: two questions may be enough. Mult Scler. 2007 Mar;13(2):215-9. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17439887" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Mohr DC, Likosky W, Bertagnolli A, Goodkin DE, Van Der Wende J, Dwyer P, Dick LP. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptoms in multiple sclerosis. J Consult Clin Psychol. 2000 Apr;68(2):356-61. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10780138" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Pandya R, Metz L, Patten SB. Predictive value of the CES-D in detecting depression among candidates for disease-modifying multiple sclerosis treatment. Psychosomatics. 2005 Mar-Apr;46(2):131-4. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15774951" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Panitch HS, Thisted RA, Smith RA, Wynn DR, Wymer JP, Achiron A, Vollmer TL, Mandler RN, Dietrich DW, Fletcher M, Pope LE, Berg JE, Miller A, Psuedobulbar Affect in Multiple Sclerosis Study Group. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006 May;59(5):780-7.</td></tr></table></p>
                    <p><table><tr><td>Rabins PV, Brooks BR. Emotional disturbance in multiple sclerosis patients: validity of the General Health Questionnaire (GHQ). Psychol Med. 1981 May;11(2):425-7. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7267880" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385-401.</td></tr></table></p>
                    <p><table><tr><td>Randolph JJ, Arnett PA, Higginson CI, Voss WD. Neurovegetative symptoms in multiple sclerosis: relationship to depressed mood, fatigue, and physical disability. Arch Clin Neuropsychol. 2000 Jul;15(5):387-98. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14590215" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am J Psychiatry. 1990 Nov;147(11):1493-7. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2221162" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Smith RA, Berg JE, Pope LE, Callahan JD, Wynn D, Thisted RA. Validation of the CNS emotional lability scale for pseudobulbar affect (pathological laughing and crying) in multiple sclerosis patients. Mult Scler. 2004 Dec;10(6):679-85. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15584494" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Sullivan MJ, Weinshenker B, Mikail S, Bishop SR. Screening for major depression in the early stages of multiple sclerosis. Can J Neurol Sci. 1995 Aug;22(3):228-31. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8529176" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Vahter L, Kreegipuu M, Talvik T, GrossPaju K. One question as a screening instrument for depression in people with multiple sclerosis. Clin Rehabil. 2007 May;21(5):460-4. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17613567" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                    <p><table><tr><td>Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med. 1997 Jul;12(7):439-45. <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9229283" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                        <h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
                    <p><div class="content_para"><p>The type of supporting evidence is identified and graded for each recommendation (see the "Major Recommendations" field).</p></div></p>

            </div>
                <h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Potential Benefits</a></h3>
                    <p><div class="content_para"><p>Appropriate assessment and management of psychiatric disorders in individuals with multiple sclerosis (MS)</p></div></p>
                        <h3><a href="#">Potential Harms</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Clinically, false-positive results are not a major concern because individuals with the conditions typically identified (e.g., adjustment and subthreshold depressive disorders) can benefit from further assessment. Administratively, screening tools with high false positive rates unnecessarily increase resource use. </li>
    <li>In a randomized controlled trial comparing dextromethorphan and quinidine (DM/Q) with placebo, dizziness was the only adverse event that occurred more frequently in the treated (26.3%) vs placebo (9.5%) group, and only one treated subject rated it as severe. </li>
</ul></p>

            </div>
                <h2 id="432" class="accordion-title section-432 is-active" role="tab" aria-expanded="true"><a href="#">Qualifying Statements</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Qualifying Statements</a></h3>
                    <p><div class="content_para"><p>This statement is provided as an educational service of the American Academy of Neurology (AAN). It is based on an assessment of current scientific and clinical information. It is not intended to include all possible proper methods of care for a particular neurologic problem or all legitimate criteria for choosing to use a specific procedure. Neither is it intended to exclude any reasonable alternative methodologies. The AAN recognizes that specific patient care decisions are the prerogative of the patient and the physician caring for the patient, based on all of the circumstances involved. The clinical context section is made available in order to place the evidence-based guideline(s) into perspective with current practice habits and challenges. Formal practice recommendations are not intended to replace clinical judgment.</p></div></p>

            </div>
                <h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Description of Implementation Strategy</a></h3>
                    <p><div class="content_para"><p>An implementation strategy was not provided.</p></div></p>
                        <h3><a href="#">Implementation Tools</a></h3>
                    <p>Patient Resources</p>
                    <p>Quick Reference Guides/Physician Guides</p>
                    <p>Resources</p>
                    <p><div class="general-block">For information about availability, see the <i>Availability of Companion Documents</i> and <i>Patient Resources</i> fields below.</div></p>

            </div>
                <h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">IOM Care Need</a></h3>
                    <p>Getting Better</p>
                    <p>Living with Illness</p>
                        <h3><a href="#">IOM Domain</a></h3>
                    <p>Effectiveness</p>
                    <p>Patient-centeredness</p>

            </div>
                <h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Bibliographic Source(s)</a></h3>
                    <p><table><tr><td>Minden SL, Feinstein A, Kalb RC, Miller D, Mohr DC, Patten SB, Bever C Jr, Schiffer RB, Gronseth GS, Narayanaswami P. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014 Jan 14;82(2):174-81. [40 references] <a href="https://web.archive.org/web/20180713033519/http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24376275" target="_blank">PubMed</a> <img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></td></tr></table></p>
                        <h3><a href="#">Adaptation</a></h3>
                    <p><div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div></p>
                        <h3><a href="#">Date Released</a></h3>
                    <p>2014 Jan 14</p>
                        <h3><a href="#">Guideline Developer(s)</a></h3>
                    <p>American Academy of Neurology - Medical Specialty Society</p>
                        <h3><a href="#">Source(s) of Funding</a></h3>
                    <p><div class="content_para"><p>This evidence-based guideline was funded by the American Academy of Neurology. No author received honoraria or financial support to develop this document.</p></div></p>
                        <h3><a href="#">Guideline Committee</a></h3>
                    <p><div class="content_para"><p>Guideline Development Subcommittee of the American Academy of Neurology</p></div></p>
                        <h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
                    <p><div class="content_para"><p><em>Guideline Authors</em>: Sarah L. Minden, MD; Anthony Feinstein, PhD, MD; Rosalind C. Kalb, PhD; Deborah Miller, PhD; David C. Mohr, PhD; Scott B. Patten, MD, PhD; Christopher Bever, Jr., MD, MBA, FAAN; Randolph B. Schiffer, MD; Gary S. Gronseth, MD, FAAN; Pushpa Narayanaswami, MBBS, DM, FAAN</p>
<p><em>2013&ndash;2015 Guideline Development Subcommittee (GDS) Members</em>: Cynthia Harden, MD (<em>Chair</em>); Steven R. Mess&eacute;, MD, FAAN (<em>Vice-Chair</em>); Richard L. Barbano, MD, PhD, FAAN; Jane Chan, MD, FAAN; Diane Donley, MD; Terry Fife, MD, FAAN; Jeffrey Fletcher, MD; Michael Haboubi, MD; John J. Halperin, MD, FAAN; Cheryl Jaigobin, MD; Andres M. Kanner, MD; Jason Lazarou, MD; David Michelson, MD; Pushpa Narayanaswami, MD, MBBS; Maryam Oskoui, MD; Tamara Pringsheim, MD; Alexander Rae-Grant, MD; Kevin Sheth, MD, FAHA; Kelly Sullivan, PhD; Theresa A. Zesiewicz, MD, FAAN; Jonathan P. Hosey, MD, FAAN (<em>Ex-Officio</em>); Stephen Ashwal, MD, FAAN (Ex-Officio); Deborah Hirtz, MD, FAAN (<em>Ex-Officio</em>); Jacqueline French, MD, FAAN (<em>Ex-Officio</em>)</p></div></p>
                        <h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
                    <p><div class="content_para"><p><strong>Conflict of Interest</strong></p>
<p>The American Academy of Neurology (AAN) is committed to producing independent, critical, and truthful clinical practice guidelines (CPGs). Significant efforts are made to minimize the potential for conflicts of interest to influence the recommendations of this CPG. To the extent possible, the AAN keeps separate those who have a financial stake in the success or failure of the products appraised in the CPGs and the developers of the guidelines. Conflict of interest forms were obtained from all authors and reviewed by an oversight committee prior to project initiation. AAN limits the participation of authors with substantial conflicts of interest. The AAN forbids commercial participation in, or funding of, guideline projects.</p>
<p><strong>Disclosures</strong></p>
<p>S. Minden has received honoraria and travel reimbursement for meetings on mood and cognition in multiple sclerosis (MS) from Pfizer, Merck-Serono, and Genentech; on fingolimod from Novartis; and on dextromethorphan and quinidine from Avanir; has received research support from the National Multiple Sclerosis Society (NMSS), the Center for Mental Health Services, and the Substance Abuse and Mental Health Services Administration; and has stock in Merck, Schering-Plough, and SmithKline.</p>
<p>A. Feinstein has received travel funding from Merck-Serono, Teva, and Bayer; is serving as a member of an editorial advisory board for MS; has received publishing royalties from the Clinical Neuropsychiatry of Multiple Sclerosis (Cambridge University Press), Journalists Under Fire (John Hopkins University Press), and Michael Rabin: America's Virtuoso Violinist (Amadeus Press); and has received honoraria from Merck-Serono, Bayer, Teva, and Biogen.</p>
<p>R. Kalb has received publishing royalties from Demos Medical Publishing and Wiley Publishing, and has received honoraria for Can Do Multiple Sclerosis.</p>
<p>D. Miller is serving as a journal editor, associate editor, or member of an editorial advisory board for Journal of Rehabilitation Research &amp; Development; and has received financial or material research support or compensation from Novartis and the NMSS.</p>
<p>D. Mohr has received research support from the NIH.</p>
<p>S. Patten is a member of the editorial board of the Canadian Journal of Psychiatry, and has received research support from the Government of Alberta's Collaborative Research Grant Initiative, the Canadian Institutes for Health Research, and the Institute of Health Economics.</p>
<p>C. Bever received travel funding from the American Academy of Neurology (AAN), the University of Maryland School of Medicine, and the Department of Veterans Affairs; has a patent held or pending for use of hematogenous stem cells in neuronal replacement therapy and gene delivery; has received funding for merit grants from the Department of Veterans Affairs and a pilot grant from the NMSS; and has received license fee payments and royalty payments (or has contractual rights for receipt of future royalty payments) related to the patent disclosed above.</p>
<p>Dr. Bever's spouse has received publishing royalties from Ambulatory Medicine, Barker et al.</p>
<p>R. Schiffer, G. Gronseth, and P. Narayanaswami have no relevant disclosures to report.</p>
<p>Go to <a href="/web/20180713033519/https://www.guideline.gov/Home/Disclaimer?id=47759&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.neurology.org%2f" title="Neurology Journal Web site">Neurology.org</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/> for full disclosures.</p></div></p>
                        <h3><a href="#">Guideline Status</a></h3>
                    <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
                        <h3><a href="#">Guideline Availability</a></h3>
                    <p><div class="content_para"><p>Electronic copies: American Academy of Neurology (AAN) guidelines, along with a link to a Portable Document Format (PDF) file for this guideline, are available at the <a href="/web/20180713033519/https://www.guideline.gov/Home/Disclaimer?id=47759&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.aan.com%2fGuidelines%2f" title="AAN Web site">AAN Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p>
<p>Print copies: Available from the AAN Member Services Center, (800) 879-1960, or from AAN, 201 Chicago Avenue South, Minneapolis, MN 55415.</p></div></p>
                        <h3><a href="#">Availability of Companion Documents</a></h3>
                    <p><div class="content_para"><p>The following are available:</p>
<ul style="list-style-type: disc;">
    <li>Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. Data supplement (e-appendices, e-references, e-tables). St. Paul (MN): American Academy of Neurology; 2014. Electronic copies: Available from the <a href="/web/20180713033519/https://www.guideline.gov/Home/Disclaimer?id=47759&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.neurology.org%2fcontent%2f82%2f2%2f174%2fsuppl%2fDC1" title="Neurology Journal Web site">Neurology Journal Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. AAN summary of evidence-based guideline for clinicians. St. Paul (MN): American Academy of Neurology; 2013. 2 p. Electronic copies: Available in Portable Document Format (PDF) from the <a href="/web/20180713033519/https://www.guideline.gov/Home/Disclaimer?id=47759&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.aan.com%2fGuidelines%2fHome%2fGetGuidelineContent%2f629" title="AAN Web site">American Academy of Neurology (AAN) Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS. Podcast. St. Paul (MN): American Academy of Neurology; 2014. Available from the <a href="/web/20180713033519/https://www.guideline.gov/Home/Disclaimer?id=47759&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.neurology.org%2fcontent%2f82%2f2%2f174%2fsuppl%2fDC2" title="Neurology Journal Web site">Neurology Journal Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
    <li>AAN guideline development process [online]. St. Paul (MN): American Academy of Neurology. Available from the <a href="/web/20180713033519/https://www.guideline.gov/Home/Disclaimer?id=47759&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.aan.com%2fGuidelines%2fHome%2fDevelopment" title="AAN Web site">AAN Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
</ul></div></p>
                        <h3><a href="#">Patient Resources</a></h3>
                    <p><div class="content_para"><p>The following is available:</p>
<ul style="list-style-type: disc;">
    <li>Emotional disorders in people with multiple sclerosis. Summary of evidence-based guideline for patients and their families. St. Paul (MN): American Academy of Neurology. 2013. 2 p. Electronic copies: Available in Portable Document Format (PDF) from the <a href="/web/20180713033519/https://www.guideline.gov/Home/Disclaimer?id=47759&amp;contentType=summary&amp;redirect=https%3a%2f%2fwww.aan.com%2fGuidelines%2fHome%2fGetGuidelineContent%2f630" title="AAN Web site">American Academy of Neurology (AAN) Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180713033519im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>. </li>
</ul>
<p class="Disclaimer">Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.</p></div></p>
                        <h3><a href="#">NGC Status</a></h3>
                    <p><div class="content_para"><p>This NGC summary was completed by ECRI Institute on March 10, 2014.</p></div></p>
                        <h3><a href="#">Copyright Statement</a></h3>
                    <p><div class="content_para"><p>This NGC summary is based on the original guideline, which is copyrighted by the American Academy of Neurology.</p></div></p>

            </div>
                <h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">NGC Disclaimer</a></h3>
                    <p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180713033519/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>

            </div>

    </div>
    <!-- /.accordion-container -->

<!-- ASIDE -->
<!-- FOOTER -->






		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				

    <!-- About NGC -->
    <div class="info-block">
            <h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
            <p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
            <ul>
                <li><a href="/web/20180713033519/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
                <li><a href="/web/20180713033519/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
                <li><a href="/web/20180713033519/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
            </ul>
            <p><a href="/web/20180713033519/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>

    </div>
    <!-- /info-block -->

    <!-- Guideline Synthesis -->

    <!-- HHS Block -->

    <!-- Related Content -->


    <hr>

    <!-- New on NGC -->
    <div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
        <ul class="subscribe-links">
            <li><a href="/web/20180713033519/https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/web/20180713033519/https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss"><span class="subscribe-links-label">RSS Feed</span></a></li>
        </ul>
    </div>
    <!-- /.subscribe-header -->
        <h5 class="prefix-icon guideline news-list-category-label">Guideline Summaries</h5>
        <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011378</li>
            <li>2017 Oct</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713033519/https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline">Mental health care in the perinatal period: Australian clinical practice guideline.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011372</li>
            <li>2015</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713033519/https://www.guideline.gov/summaries/summary/51294/clinical-practice-guideline-on-systemic-lupus-erythematosus">Clinical practice guideline on systemic lupus erythematosus.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011385</li>
            <li>2018 Mar</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713033519/https://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy">VA/DoD clinical practice guideline for the management of pregnancy.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011376</li>
            <li>2018 Feb</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713033519/https://www.guideline.gov/summaries/summary/51298/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011370</li>
            <li>2017 Dec</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180713033519/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society">The implementation of targeted temperature management: an evidence-based guideline from the Neurocritical Care Society.</a></p>
    </div>

    <a class="block-link" href="/web/20180713033519/https://www.guideline.gov/new-this-week/index">
        <h3>New This Week </h3>
        <p>View more and sign up for our Newsletter</p>
    </a>
    <!-- Adobe Reader -->
    <p><a href="/web/20180713033519/https://www.guideline.gov/disclaimer?id=47759&amp;contentType=summary&amp;redirect=http%3A%2F%2Fget.adobe.com%2Freader%2F" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	



    <!-- COMMENTS -->
    

</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source type="image/svg+xml" srcset="/web/20180713033519im_/https://www.guideline.gov/UI/images/logo_NGC_footer.svg">
					  	<img src="/web/20180713033519im_/https://www.guideline.gov/UI/images/logo_NGC_footer.png" alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/web/20180713033519/https://www.guideline.gov/">Home</a></li>
		                <li><a href="/web/20180713033519/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="/web/20180713033519/https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/web/20180713033519/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/web/20180713033519/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="/web/20180713033519/https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="/web/20180713033519/https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/web/20180713033519/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/web/20180713033519/https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="/web/20180713033519/https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="/web/20180713033519/https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="/web/20180713033519/https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/web/20180713033519/https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/web/20180713033519/https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/web/20180713033519/https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/web/20180713033519/https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/web/20180713033519/https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/web/20180713033519/https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://web.archive.org/web/20180713033519/https://www.qualitymeasures.ahrq.gov/" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/web/20180713033519im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.svg">
									<img src="/web/20180713033519im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://web.archive.org/web/20180713033519/https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/web/20180713033519im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.svg">
								    <img src="/web/20180713033519im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="https://web.archive.org/web/20180713033519/http://www.facebook.com/" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.twitter.com/" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.linkedin.com/" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.youtube.com/" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="https://web.archive.org/web/20180713033519/http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//web.archive.org/web/20180713033519js_/https://ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/web/20180713033519js_/https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
<!--
     FILE ARCHIVED ON 03:35:19 Jul 13, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 16:46:46 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 264.468 (3)
  esindex: 0.004
  captures_list: 280.616
  CDXLines.iter: 10.797 (3)
  PetaboxLoader3.datanode: 135.958 (4)
  exclusion.robots: 0.117
  exclusion.robots.policy: 0.109
  RedisCDXSource: 3.087
  PetaboxLoader3.resolve: 139.059
  load_resource: 172.079
-->